About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$9.82
Change (%) Stock is Down 0.03 (0.30%)
Volume183,404
Data as of 01/18/17 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $9.82 with a 52 week high of $13.80 and a 52 week low of $6.52.

Recent News

Natera Announces Results From DNAFirst Study, Validating Use Of NIPT In Routine Prenatal Care - 01/17/17
Results demonstrate clinical utility of NIPT as first line screen in a general population Study results published in Genetics in Medicine SAN CARLOS, Calif., Jan. 17, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive... More»
Natera Inc. Terminates NIPT Distribution Agreement with Bioreference Labs - 01/10/17
SAN CARLOS, Calif., Jan. 10, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced the termination of a distribution agreement with Bioreference Laboratories. With the ending of the distribution agreement, Na... More»
Natera Provides Constellation™ Update - 12/21/16
Cloud-based software platform continues to fuel growth and expansion into international markets SAN CARLOS, Calif., Dec. 21, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the availab... More»
Natera Announces Participation In I-SPY 2 TRIAL For Breast Cancer - 12/14/16
Natera to evaluate the effectiveness of liquid biopsy in monitoring breast cancer SAN CARLOS, Calif., Dec. 14, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free ... More»
The Centers For Medicare And Medicaid Services Establishes 2017 Pricing For Aneuploidy And Microdeletion Testing - 12/01/16
SAN CARLOS, Calif., Dec. 1, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA announced today that the Centers for Medicare & Medicaid Services (CMS) released final ... More»

Upcoming Events

There are currently no events scheduled.

Recent Presentations

There are currently no items available.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools